Skip to content
DeepViews

Anbio Biotechnology Class A Ordinary Shares (NNNN) — 分析摘要

Anbio Biotechnology Class A Ordinary Shares(NNNN)的市值为341.47百万美元,最近一年的营收同比增长了+5.6%。净利润率为74.1%。当前市盈率为53.3倍。

核心要点

  • 营收同比变化+5.6%
  • 净利润率74.1%
  • 市盈率53.3倍

NNNN的营收增长为+5.6%,市盈率为53.3倍。

[XNAS]

Anbio Biotechnology Class A Ordinary Shares (NNNN)

$7.67

更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$341.47M
企业价值
$329.57M
市盈率
53.3
股息率
0.00%
EV/EBITDA
N/A
公司简介
关于
关于 Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

员工人数

27

Exchange

XNAS

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒

需要至少 3 年年度财务数据来评估竞争壁垒。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$30.16M
总债务$0.00M
债务权益比0.00
现金及等价物$7.77M

现金流

经营现金流$-6.74M
自由现金流$0.00M
自由现金流率0.00%
P/FCF 比率N/A
Source: Polygon.io · SEC EDGAR
股息
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。